Related Experiment Video
Updated: Sep 2, 2025
10:20
In vitro Measurements of Tracheal Constriction Using Mice
Published on: June 25, 2012
20.9K
Anticholinergics in Chronic Asthma: A Promising Future?
1Department of Pediatrics, University of New Mexico, Albuquerque, New Mexico.
Pediatric Allergy, Immunology, and Pulmonology
|August 5, 2022
Summary
Long-acting anticholinergics like tiotropium bromide show promise for improving asthma control. Early studies suggest benefits in lung function and symptoms for adults not adequately managed with inhaled corticosteroids alone.
Area of Science:
- Pulmonology
- Pharmacology
Background:
- Anticholinergics have a long history as asthma bronchodilators but lack FDA approval for general asthma treatment.
- Short-acting inhaled anticholinergics have not demonstrated improved outcomes in chronic persistent asthma.
- Ipratropium bromide is recommended for severe acute asthma exacerbations to reduce hospitalizations.
Purpose of the Study:
- To evaluate the efficacy of long-acting anticholinergics in adult asthma patients.
- To compare tiotropium bromide add-on therapy with increased inhaled corticosteroid dosage.
Main Methods:
- A recent clinical trial investigated the effects of tiotropium bromide in adult asthma patients.
- Patients were inadequately controlled on inhaled corticosteroid monotherapy.
Main Results:
- Tiotropium bromide improved lung function and asthma symptom impairment outcomes.
- The observed effects were comparable to adding a long-acting beta2 agonist.
- Improvements were noted when compared to doubling the inhaled corticosteroid dose.
Conclusions:
- Long-acting anticholinergics, specifically tiotropium bromide, show potential as an add-on therapy for asthma.
- Further research is required to ascertain if tiotropium bromide can decrease asthma exacerbation risk.
Related Concept Videos
01:20Antiasthma Drugs: Muscarinic Receptor Antagonists
417
Muscarinic receptor antagonists, also known as antimuscarinic agents, are a class of bronchodilators used to treat asthma, although they are more commonly used to treat COPD. They work by inhibiting the action of acetylcholine (ACh), a neurotransmitter, on muscarinic receptors found in the airways.
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...
417
01:25Antiasthma Drugs: β2-Adrenoceptor Agonists
354
Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
354
01:26Cholinergic Antagonists: Therapeutic Uses
822
Antimuscarinic drugs have various therapeutic applications by inhibiting parasympathetic stimulation in different systems. Here are the key therapeutic uses of antimuscarinics:
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal...
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal...
822
01:30Indirect-Acting Cholinergic Agonists: Pharmacological Actions
756
Indirect-acting cholinergic agonists, also known as anticholinesterases, exert their pharmacological effects by enhancing cholinergic transmission in various body parts, including the neuromuscular junction, autonomic cholinergic synapses, and the brain.
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
756
01:11Direct-Acting Cholinergic Agonists: Therapeutic Uses
841
Direct-acting cholinergic agonists have many therapeutic uses in various medical fields. Choline esters, including acetylcholine, have limited clinical utility due to their non-selectivity and short duration of action. Still, acetylcholine and carbachol are applied topically during ophthalmologic surgery to induce miosis. Pilocarpine, a muscarinic and ganglionic stimulator, effectively treats open-angle glaucoma and alleviates xerostomia and dry mouth caused by radiotherapy or Sjögren...
841
01:24Cholinergic Antagonists: Pharmacokinetics
552
Cholinergic antagonists—such as antimuscarinics—are available in oral, topical, ocular, parenteral, and inhalational formulations. Most antimuscarinics are oral formulations, while scopolamine is available as a topical patch, and ipratropium and tiotropium are available as inhalation aerosols or powders. Atropine, tropicamide, and cyclopentolate are topically instilled in the eye. Most antimuscarinics are lipid-soluble and readily absorbed from the gastrointestinal tract and...
552